Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply
Tom2772
Tom2772 Aug. 25 at 7:57 PM
$OTLK $REGN $RHHBY Btw.. LYTENAVA does not need to replace Eylea HD or Vabysmo to be commercially relevant. It offers an FDA-approved nAMD option alongside the compounded bevacizumab that has been widely used off-label.
0 · Reply
ajbski
ajbski Aug. 25 at 2:54 PM
$NVAX 🚨Novavax unnamed partner for the immuno-oncology MTA is a "top-10 global pharmaceutical company and global oncology leader." Industry analysts identify the most likely candidate as: 1) Merck & Co. $MRK 2) AstraZeneca $AZN 3) Roche/Genentech $RHHBY 4) Bristol Myers Squibb $BMY https://share.google/aimode/lR4vGA4S3vSo6P42t
1 · Reply
Makingmillions192
Makingmillions192 Aug. 25 at 12:50 PM
$LEXX This industry is ripe for deals and acquisitions 🔥 Our time is coming ⏰ https://www.biopharmadive.com/news/roche-lean-mass-preservation-hanmi-obesity-deal/828579/ $RHHBY $LLY $NVO $PFE
0 · Reply
MQuick
MQuick Aug. 25 at 12:50 PM
$GANX its time $SNY $RHHBY $MRKR
0 · Reply
Makingmillions192
Makingmillions192 Aug. 24 at 4:33 PM
$LEXX It’s becoming apparent that if a competitor like Eli Lilly, Viking Therapeutics, or Roche licenses DehydraTECH, they get an immediate, unencumbered pathway to build high-absorption oral weight-loss pills without needing SNAC or infringing on Novo’s patents. Novo Nordisk may want to secure or buy out DehydraTECH purely to block rivals from leapfrogging Rybelsus® and oral Wegovy®. If Novo Nordisk wants oral Amycretin or oral semaglutide to have higher bio-absorption, lower manufacturing costs, and significantly fewer GI side effects, DehydraTECH represents a turnkey solution. Whether Novo steps up first or a rival (like Eli Lilly or a Tier-1 licensee via Liberi Group) makes a move, today’s data makes Lexaria’s IP a prime target for strategic acquisition or licensing. Human study #7 due any day ⏰ $NVO $LLY $VKTX $RHHBY
0 · Reply
imatisse
imatisse Aug. 24 at 4:27 PM
By nature, $RHHBY is a large, process-driven company / long-term-focus. Once they fully commit to an area (as they did with antibodies back in the day), they build the organization, workforce, and infrastructure around it. That process is clearly underway in the field of ‘Cell-Therapy’ and has been for a few years now #OpRegen -> #GAlette @17sites #AlloSCOPE $LCTX ($50,8m cash)
0 · Reply
HawkEye828
HawkEye828 Aug. 24 at 1:06 PM
$PROK Nice Accumulation going on with this stock. Buy and Hold. Here is More educational info on Prok. This is a big deal! Government savings would be huge. National Kidney Foundation indicates Medicare actually spends $130 Bilion--moe then 24% of total spending on kidney disease. https://www.kidney.org/take-action/advocate/legislative-priorities/federal-investment J.P. Morgan conference--Phase 2 complete. 78% response rate with kidney stabilization. This is an Autologous treatment, using the patients own kidney cells. Alligned with FDA for Accelerated approval. Phase 3 on board. https://investors.prokidney.com/static-files/9159cbbe-5e36-468c-9c58-f3b3cc4fc428 $MRNA, $RHHBY, $LLY, $ABBV
0 · Reply
scdtrader213
scdtrader213 Aug. 24 at 12:17 PM
$RHHBY said the FDA has cleared its Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test to aid in identifying amyloid pathology associated with Alzheimer’s disease in people aged 55 and older experiencing cognitive decline.
0 · Reply
MQuick
MQuick Aug. 24 at 11:57 AM
$GANX its time $SNY or $RHHBY
0 · Reply
Latest News on RHHBY
No data available.
Tom2772
Tom2772 Aug. 26 at 2:57 PM
$REGN $ABBV $RHHBY Interesting LYTENAVA Interview This interview is already about a week old, but it’s still very interesting and worth highlighting. A sponsored, retina-focused interview for the U.S. LYTENAVA rollout, aimed less at investors and more at raising awareness within the medical community — especially among retina specialists — ahead of the U.S. launch. Bob Jahr, CEO of Outlook Therapeutics, discusses the FDA approval, LYTENAVA, and its path into retina practice. Dr. Barry Kuppermann, MD, PhD, moderates the interview. He is a practicing retina specialist, Professor and Chair of Ophthalmology & Visual Sciences, as well as Director of the Gavin Herbert Eye Institute at UC Irvine. This puts LYTENAVA directly in front of the medical audience that matters for the U.S. launch. Interesting.. very interesting.. 👀 https://eyetube.net/podcasts/new-retina-radio/the-story-behind-lytenava-from-fda-approval-to-retina-practice
0 · Reply
Tom2772
Tom2772 Aug. 25 at 7:57 PM
$OTLK $REGN $RHHBY Btw.. LYTENAVA does not need to replace Eylea HD or Vabysmo to be commercially relevant. It offers an FDA-approved nAMD option alongside the compounded bevacizumab that has been widely used off-label.
0 · Reply
ajbski
ajbski Aug. 25 at 2:54 PM
$NVAX 🚨Novavax unnamed partner for the immuno-oncology MTA is a "top-10 global pharmaceutical company and global oncology leader." Industry analysts identify the most likely candidate as: 1) Merck & Co. $MRK 2) AstraZeneca $AZN 3) Roche/Genentech $RHHBY 4) Bristol Myers Squibb $BMY https://share.google/aimode/lR4vGA4S3vSo6P42t
1 · Reply
Makingmillions192
Makingmillions192 Aug. 25 at 12:50 PM
$LEXX This industry is ripe for deals and acquisitions 🔥 Our time is coming ⏰ https://www.biopharmadive.com/news/roche-lean-mass-preservation-hanmi-obesity-deal/828579/ $RHHBY $LLY $NVO $PFE
0 · Reply
MQuick
MQuick Aug. 25 at 12:50 PM
$GANX its time $SNY $RHHBY $MRKR
0 · Reply
Makingmillions192
Makingmillions192 Aug. 24 at 4:33 PM
$LEXX It’s becoming apparent that if a competitor like Eli Lilly, Viking Therapeutics, or Roche licenses DehydraTECH, they get an immediate, unencumbered pathway to build high-absorption oral weight-loss pills without needing SNAC or infringing on Novo’s patents. Novo Nordisk may want to secure or buy out DehydraTECH purely to block rivals from leapfrogging Rybelsus® and oral Wegovy®. If Novo Nordisk wants oral Amycretin or oral semaglutide to have higher bio-absorption, lower manufacturing costs, and significantly fewer GI side effects, DehydraTECH represents a turnkey solution. Whether Novo steps up first or a rival (like Eli Lilly or a Tier-1 licensee via Liberi Group) makes a move, today’s data makes Lexaria’s IP a prime target for strategic acquisition or licensing. Human study #7 due any day ⏰ $NVO $LLY $VKTX $RHHBY
0 · Reply
imatisse
imatisse Aug. 24 at 4:27 PM
By nature, $RHHBY is a large, process-driven company / long-term-focus. Once they fully commit to an area (as they did with antibodies back in the day), they build the organization, workforce, and infrastructure around it. That process is clearly underway in the field of ‘Cell-Therapy’ and has been for a few years now #OpRegen -> #GAlette @17sites #AlloSCOPE $LCTX ($50,8m cash)
0 · Reply
HawkEye828
HawkEye828 Aug. 24 at 1:06 PM
$PROK Nice Accumulation going on with this stock. Buy and Hold. Here is More educational info on Prok. This is a big deal! Government savings would be huge. National Kidney Foundation indicates Medicare actually spends $130 Bilion--moe then 24% of total spending on kidney disease. https://www.kidney.org/take-action/advocate/legislative-priorities/federal-investment J.P. Morgan conference--Phase 2 complete. 78% response rate with kidney stabilization. This is an Autologous treatment, using the patients own kidney cells. Alligned with FDA for Accelerated approval. Phase 3 on board. https://investors.prokidney.com/static-files/9159cbbe-5e36-468c-9c58-f3b3cc4fc428 $MRNA, $RHHBY, $LLY, $ABBV
0 · Reply
scdtrader213
scdtrader213 Aug. 24 at 12:17 PM
$RHHBY said the FDA has cleared its Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test to aid in identifying amyloid pathology associated with Alzheimer’s disease in people aged 55 and older experiencing cognitive decline.
0 · Reply
MQuick
MQuick Aug. 24 at 11:57 AM
$GANX its time $SNY or $RHHBY
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 23 at 8:57 PM
Looking at Top 10 Part B Drugs By Total Spending Q1, 2026, how many more quarters do you think the 2 listed drugs that can be used for wet AMD may see 550m, and 350m or higher again? $REGN $RHHBY $BAYRY $OTLK https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-quarterly-part-b-spending-by-drug
1 · Reply
Tom2772
Tom2772 Aug. 23 at 4:20 PM
$OTLK $REGN $RHHBY This article and video is particularly relevant to OTLK because it examines LYTENAVA from the perspective of Dr. Carolyn Majcher, OD, FAAO, a clinical expert and former Chief of a retinal disease clinic. According to Majcher, compounded bevacizumab has been widely used off-label for years. For optometrists, the recent FDA approval instills confidence in using the FDA-approved product for nAMD. LYTENAVA does not need to replace Eylea HD or Vabysmo to be commercially relevant. It offers an FDA-approved nAMD option alongside the compounded bevacizumab that has been widely used off-label. 👀 worth a look! https://www.optometrytimes.com/view/how-lytenava-fda-approval-will-impact-clinical-treatment-namd
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 23 at 10:26 AM
$RHHBY https://www.fiercepharma.com/manufacturing/roche-earmarks-750m-double-size-its-manufacturing-facility-oregon
0 · Reply
imatisse
imatisse Aug. 22 at 4:38 PM
$RHHBY De nombreux indices “tea/leaf” laissent désormais penser que #Roche #Genentech considère sérieusement #OpRegen $LCTX ($50,8m cash) comme un produit potentiellement commercialisable, y compris au niveau de la distribution + fabrication! #GAlette @17sites #AlloSCOPE ❤️
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 21 at 6:48 PM
$MRNA Bye Buy Short Turdler -- we hardly knew ya. onto the next ID. $SLS Should be at $24/$28 When the 80th Event PR is announced / imminently. SLS share price has nearly doubled and more every time an Event Milestone was announced. IDMC Unblinded the actual MOS and IR Data --- from the Interim Analysis. - Thought exercise - BAT is known, it failed 3 Large Phase 3 Trials, conducted by $ABBV / $RHHBY $BMY They KNOW PRECISELY how thier Drugs Perform for these AML CR2 patients.
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 20 at 8:18 PM
$RHHBY $NVS $HROW $OTLK
0 · Reply
M3l1MCK
M3l1MCK Aug. 19 at 4:34 PM
$LMDX $RHHBY looking at Roche's price right now is making me quite hungry!!!! We need to be paid our due!!!!
0 · Reply
HawkEye828
HawkEye828 Aug. 19 at 1:39 PM
Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV
1 · Reply
Quantumup
Quantumup Aug. 19 at 11:55 AM
Mizuho⬇️ $LONA's PT to $15 on higher OpEx & stayed Outperform after LONA reported 2Q26 results last Friday (8/14) $AZN $RHHBY NVS LLY PFE - ARVN CELC RLAY SNY BIIB IONS AMLX DNLI BIOA ELDN Mizuho said -- We caught up with management yesterday, and most importantly, LONA's Phase 3 ELAINE-3 study for lead asset lasofoxifene/laso (a selective estrogen receptor modulator/SERM) in treatment-resistant ER+/HER2-ESR1-mutant metastatic breast cancer/BrCa continues to advance, with key milestones (trial enrollment completion in 4Q26, and top-line data in 2H27) still on track. We also discussed progress with the company's ALS asset (ATH-1105, but now called brelgometon) and the company's current finances, but bigger picture, we leave with our positive thesis on LONA intact. On a model update (higher OpEx), we adjust our PT from $16 to $15, but with an implied 95% share upside potential, and in our view, an underappreciated laso market opportunity in breast cancer, we maintain our OP rating on LONA.
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:53 PM
$RHHBY The latest 13F tracking shows 38 institutional buyers versus 25 sellers over the last 12 months. Huge support
0 · Reply
scdtrader213
scdtrader213 Aug. 18 at 3:51 PM
$RHHBY strong chart indicating 60 is next
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 17 at 3:46 PM
$OTLK $RHHBY Is anyone hopeful of a #miscellaneous #surprise? 1. For bevacizumab use in eyes: even if DME and RVO are off label in 2026-unknown, why might an ophthalmologist often choose vs not often choose compounded for: #dme and #rvo as opposed to something still off label for those 2, but with FDA approval for wet AMD indication? 2. How important is safety, efficacy, and affordability to patients, health insurers, and ophthalmologists? 3. Historically, for any injection of compounded bevacizumab for adults, has the volume of bevacizumab been the same regardless of indication? 4. Does anyone know if there’s a general J code for off label indication injections like J3490 or J3590 maybe? 5. Is there possibly any kind of miscellaneous code in Europe for off label use for DME or RVO, or does it vary by country?
0 · Reply